Pharmaceuticals, Biotechnology & Life Sciences

Discover how Novo Nordisk’s new leadership shake‑up, Wegovy pill rollout in Germany, and 2 mg Ozempic launch in Norway are reshaping the obesity drug market and driving investor upside.

Explore how CERENOME INC, a Nasdaq‑listed biotech in Austin, Texas, is advancing cancer and life‑threatening therapeutics while navigating market swings and regulatory shifts.

Satellos Bioscience: Toronto biotech innovating skeletal muscle regeneration, promising new therapies for muscle disorders and a bright future in regenerative medicine.

Verastem’s quest to develop RAF, MEK and FAK‑inhibitor cancer therapies faces steep financial, regulatory and market hurdles—can the biotech firm turn promise into profit?

Vanda Pharmaceuticals, a biotech leader, develops small‑molecule drugs for CNS disorders. Despite a negative P/E, its clinical‑stage pipeline promises breakthrough treatments that could boost investor confidence and market value.

Inovio Pharmaceuticals advances DNA vaccine breakthroughs, partnering with oncology leaders to boost antitumor therapy, while expanding R&D for infectious and cancer treatments.

Immutep Limited’s 2026 loss deepens as R&D costs soar, prompting investors to weigh short‑term pain against future breakthrough potential.

Tilray Brands sees execs buy back shares, boosting confidence in its cannabis growth strategy and global market leadership.

FDA approves Protagonist’s MIMRYLO, the first peptide therapy for polycythemia vera, cutting phlebotomy use and boosting patient energy.

Gerresheimer AG sees leadership change, Q1 2026 revenue rise 1% yet EBITDA slumps 17 m, amid market volatility and investor scrutiny.